Gilead Sciences Set to Report Strong Q1 Earnings Results

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a prominent biopharmaceutical firm dedicated to developing innovative therapies for various diseases, including HIV, liver conditions, cancer, and inflammation. The company currently holds a market capitalization of $129 billion.

Quarterly Earnings Anticipation

Gilead is scheduled to announce its fiscal Q1 earnings after market hours on Thursday, April 24. Analysts predict that GILD will report earnings of $1.73 per share, a significant turnaround from a loss of $1.32 per share in the same quarter last year. The company has consistently exceeded Wall Street’s earnings expectations for the past four quarters, showcasing significant market strength.

Future Earnings Projections

For fiscal year 2025, analysts forecast GILD will report an EPS of $7.86, reflecting a 70.1% increase from $4.62 in fiscal 2024. The EPS is expected to grow by another 5.6% annually to reach $8.30 in fiscal year 2026.

Stock Performance Overview

GILD Stock has experienced substantial growth, increasing by 51% over the past year. This performance notably outpaces the S&P 500’s ($SPX) gain of 3.2% and the Health Care Select Sector SPDR Fund’s (XLV) decline of 2.9% during the same period.

Recent Market Reactions

On March 20, shares of Gilead Sciences fell by 2.5% following news that the Department of Health and Human Services is contemplating budget cuts to federal funding for HIV prevention initiatives. Gilead is recognized for its strong portfolio in HIV treatments, including preventative options such as Descovy and Truvada, and the announcement prompted concern among investors.

Analyst Ratings and Price Targets

Overall, the consensus rating for GILD Stock is cautiously optimistic, with a “Moderate Buy” assessment from analysts. Of the 29 analysts monitoring the stock, 17 recommend a “Strong Buy,” while 12 suggest a “Hold.”

The average analyst price target for GILD stands at $112.20, suggesting an upside potential of 8.3% based on current trading levels.

On the date of publication, Kritika Sarmah did not hold (either directly or indirectly) any positions in the securities mentioned in this article. All information provided is for informational purposes only. For further details, please view the Barchart Disclosure Policy here.

More news from Barchart

The views expressed in this article are those of the author and do not necessarily reflect those of Nasdaq, Inc.